Latest News:

Tufts CSDD Demonstrates Multi-Million-Dollar Benefits of Translational Pharmaceutics®

Downloading our Whitepaper

You are about to download this document, please enter your contact details below to start downloading.

Whitepaper

Assessing the Financial Impact of Translational Pharmaceutics®

Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.

Would you like to receive further scientific content including case studies, whitepapers and seminar and webinar invitations?
You can find out how we handle your personal information in our privacy policy here.

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.